Press coverage about Chimerix (NASDAQ:CMRX) has been trending positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Chimerix earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.8575448890642 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

Chimerix (NASDAQ:CMRX) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%.

A number of analysts have weighed in on the stock. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Wednesday, August 9th. ValuEngine cut shares of Chimerix from a “hold” rating to a “sell” rating in a report on Friday, August 11th.

COPYRIGHT VIOLATION WARNING: “Favorable Press Coverage Somewhat Unlikely to Affect Chimerix (CMRX) Stock Price” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Insider Buying and Selling by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with's FREE daily email newsletter.